Alcohol Clinical and Experimental Research, Год журнала: 2024, Номер unknown
Опубликована: Дек. 30, 2024
Alcohol-associated hepatitis (AH) is a subtype of alcohol-associated liver disease (ALD) resulting in severe acute inflammation. This study aims to examine longitudinal trends mortality from AH the United States (US) 1999 2020, stratifying data by sex, age, and racial/ethnic groups.
Язык: Английский
Metabolism, Год журнала: 2024, Номер 158, С. 155958 - 155958
Опубликована: Июнь 26, 2024
Язык: Английский
Процитировано
28
Alimentary Pharmacology & Therapeutics, Год журнала: 2024, Номер 60(3), С. 340 - 349
Опубликована: Май 29, 2024
Summary Backgrounds and Aims Alcohol use leads to disabilities deaths worldwide. It not only harms the liver but also causes alcohol disorder (AUD) heart disease. Additionally, consumption contributes health disparities among different socio‐economic groups. Methods We estimated global regional trends in burden of AUD, disease, cardiovascular disease from using methodology Global Burden Disease study. Results In 2019, highest disability‐adjusted life years rate per 100,000 population was due AUD (207.31 [95% Uncertainty interval (UI) 163.71–261.66]), followed by alcohol‐associated (ALD) (133.31 UI 112.68–156.17]). The prevalence decreased for (APC [annual percentage change] −0.38%) alcohol‐induced cardiomyopathy −1.85%) increased ALD 0.44%) cancer 0.53%). Although mortality 0.30%), rates other diseases decreased. Between 2010 complications countries with low low‐middle sociodemographic index (SDI), contributing more significantly burden. Conclusion liver, has been high increasing over past decade, particularly complications. Lower SDI are this There is a pressing need effective strategies address escalating
Язык: Английский
Процитировано
16
Clinical and Molecular Hepatology, Год журнала: 2025, Номер unknown
Опубликована: Янв. 9, 2025
Alcohol represents a leading burden of disease worldwide, including alcohol use disorder (AUD) and alcohol-related liver (ALD). We aim to assess the global AUD, ALD, alcohol-attributable primary cancer between 2000-2021. registered regional trends using data from Global Burden Disease 2021 Study, largest most up-to-date epidemiology database. estimated annual percent change (APC) its 95% confidence interval (CI) changes in age-standardized rates over time. In 2021, there were 111.12 million cases 3.02 132,030 cancer. Between 2000 was 14.66% increase 38.68% 94.12% prevalence. While prevalence rate for increased (APC: 0.59%, [CI] 0.52 0.67%) these years, it decreased ALD -0.71%, CI -0.75 -0.67%) AUD -0.90%, -0.94 -0.86%). There significant variation by region, socioeconomic development level, sex. During last years (2019-2021), prevalence, incidence, death greater extent females. Given high cancer, urgent measures are needed prevent them at both national levels.
Язык: Английский
Процитировано
5
Alimentary Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown
Опубликована: Янв. 31, 2025
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promise in reducing alcohol consumption, but their impact on clinical outcomes patients with use disorder (AUD) remains unclear. We investigated the association between GLP-1RAs and development progression of alcohol-related liver disease (ArLD) AUD. Using TriNetX Research Network, we conducted two retrospective cohort studies comparing versus dipeptidyl peptidase-4 inhibitors (DPP-4is) type 2 diabetes. The first included AUD without ArLD (n = 7132 after propensity score matching), while second comprised established 1896 matching). Primary were incident hepatic decompensation cohort. In (median follow-up: 63.2 months), GLP-1RA users showed significantly lower risks developing compared to DPP-4i (incidence rate: 6.0 vs. 8.7 per 1000 person-years; HR: 0.62, 95% CI: 0.44-0.87, p 0.006). also associated reduced all-cause mortality (HR: 0.53, < 0.001). 28.2 demonstrated 39.5 51.4 0.66, 0.51-0.85, 0.001) users. progressing AUD, suggesting potential therapeutic benefits this population.
Язык: Английский
Процитировано
1
Journal of Gastroenterology and Hepatology, Год журнала: 2024, Номер 39(11), С. 2456 - 2463
Опубликована: Авг. 22, 2024
Abstract Background and Aim Metabolic dysfunction‐associated steatotic liver disease (MASLD) has become a leading cause of chronic worldwide. A new entity termed MetALD also been described is defined as individuals with MASLD increased alcohol intake. However, the natural history compared unknown. We aimed to compare longitudinal outcomes in patients versus MetALD. Methods This study was performed using data from National Health Nutrition Examination Survey 2011 2018. (defined by United States Fatty Liver Index > 30) who met cardiometabolic criteria including body mass index (BMI) 25 (BMI 23 Asians), hypertension, diabetes mellitus, dyslipidemia, hypertriglyceridemia were included. intake (3–6 standard drinks per day males; 2–5 females). comparison overall, cardiovascular, cancer‐related, other causes mortality performed. Results total 2838 2557 included median follow‐up time 56 months. at risk cancer‐related (hazard ratio 1.32; 95% confidence interval 1.14–1.53; P < 0.01). there no significant difference mortality. Conclusions Patients higher for than MASLD. Close attention regular cancer surveillance accurate classification consumption diagnosed warranted help improve patient care outcome.
Язык: Английский
Процитировано
8
Scientific Reports, Год журнала: 2024, Номер 14(1)
Опубликована: Авг. 22, 2024
Primary liver cancer is the third leading cause of cancer-related mortality. The increasing prevalence metabolic syndrome and alcohol consumption, along with existing burden viral hepatitis, could significantly heighten impact primary cancer. However, specific effects these factors in Asia–Pacific region, which comprises more than half global population, remain largely unexplored. This study aims to analyze epidemiology region. We evaluated regional national data from Global Burden Disease spanning 2010 2019 assess age-standardized incidence, mortality, disability-adjusted life years associated During period, there were an estimated 364,700 new cases 324,100 deaths, accounting for 68 67% totals, respectively. Upward trends observed incidence rates due dysfunction-associated fatty disease (MASLD) alcohol-associated (ALD) as well increase Hepatitis B virus infection Western Pacific Notably, approximately 17% occurred individuals aged 15–49 years. Despite overall decline region over past decade, increases noted several etiologies, including MASLD ALD. hepatitis remains cause, responsible 60% total burden. These findings underscore urgent need comprehensive strategies address rising
Язык: Английский
Процитировано
6
Alimentary Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown
Опубликована: Янв. 16, 2025
ABSTRACT Introduction Alcohol‐associated liver disease (ALD) disproportionately impacts men, racial and ethnic minorities, individuals of low socioeconomic status; however, it's unclear how recent increases in ALD burden have impacted these disparities. We aimed to describe trends racial, disparities alcohol‐associated hospital encounters. Methods conducted a retrospective cohort study adult encounters with diagnoses from three health systems between January 2016 December 2021. The was divided into eras: ‘Historical Era,’ (Oct 2016—June 2018, used only for trends); ‘Era 1’ (July 2018—March 2020); 2’ (April 2020—December 2021). Kaplan Meier Cox regression analyses were performed identify factors associated overall survival. Results identified 19,295 (44.7% White, 29.8% Hispanic, 21.8% non‐Hispanic Black (NHB) individuals), greater increase observed eras 1 2 than the historical era Era (8.7% vs. 5.0%, p < 0.01). By age sex, greatest youngest oldest females but males. race ethnicity, Hispanic had compared White (14.8% 7.5% 6.3%, Older (aSHR: 1.03, 95% CI: 1.03–1.0), higher MELD 1.08, 1.0–1.09), hepatic encephalopathy 1.42, 1.06–1.90), hepatocellular carcinoma (HCC) 3.20, 2.29–4.49) increased mortality. Conclusion highest amongst young NHB women, highlighting variation by age, ethnicity. These merit further investigation elucidate underlying mechanisms develop tailored interventions improve outcomes.
Язык: Английский
Процитировано
0
Alimentary Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown
Опубликована: Янв. 23, 2025
We deeply appreciate the insightful letter from Liu and He et al., which highlights their analysis of global burden metabolic dysfunction-associated steatotic liver disease (MASLD)-related cancer using Global Burden Disease Study (GBD) 2021 database [1]. The similarities between findings our observations on rising MASLD-related in United States underscore importance this issue [2]. data trends cancer, particularly notable increases incidence mortality, are highly significant. Prior studies same also emphasised disease-related with increasing age-standardised rates for both alcohol-associated (ALD) (APC: 0.26%, 95% CI 0.22%–0.30%) MASLD 0.62%, 0.58%–0.67%) [3, 4]. non-overlapping confidence intervals support assertion, as noted by that is a primary driver disease, evidenced projections through 2050 However, several limitations to GBD methodology warrant consideration [5]. For example, alcohol use frequently underreported, could result some cases being reclassified dysfunction (MetALD) or ALD [6, 7]. A comprehensive history, including recent lifetime intake, essential ensure accurate prognosis management. Consideration alcohol's impact syndrome criteria, reassessing over time, addressing challenges underreporting biomarkers, validated questionnaires collateral information [6]. Furthermore, since 2024, Resmetirom has received conditional approval treating MASH, while treatment advancements have lagged behind, suggesting future may increase more than [8, 9]. further underscores critical need incorporate demographic factors, population aging, into strategies preventing managing cancer. This extends ALD-associated disorder shows similar prevalence general [10]. Such insights can guide development tailored public health resource allocation effectively address these populations' unique needs, will translate prevention Further refinement large-scale databases accurately quantify aetiology-specific contributions, globally, informing efforts, target populations, reduce mortality. Pojsakorn Danpanichkul: writing – original draft. Donghee Kim: review editing. Markos Kalligeros: Amit G. Singal: Ju Dong Yang: Karn Wijarnpreecha: Yang consults AstraZeneca, Eisai, Exact Sciences FujiFilm Medical Sciences. Singal served consultant advisory boards Genentech, Exelixis, Bayer, Elevar, Boston Scientific, Sirtex, Histosonics, Sciences, Roche, Abbott, Glycotest, Freenome GRAIL. authors' declarations personal financial interests unchanged those article linked Danpanichkul al papers. To view articles, visit https://doi.org/10.1111/apt.18473 https://doi.org/10.1111/apt.18510. authors nothing report.
Язык: Английский
Процитировано
0
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Alimentary Pharmacology & Therapeutics, Год журнала: 2024, Номер 60(4), С. 521 - 522
Опубликована: Июль 5, 2024
LINKED CONTENT This article is linked to Danpanichkul et al papers. To view these articles, visit https://doi.org/10.1111/apt.18101 and https://doi.org/10.1111/apt.18140
Язык: Английский
Процитировано
3